Pertussis Vaccine
Diphtheria-Tetanus-acellular Pertussis Vaccines
Vaccines, Acellular
Whooping Cough
Diphtheria-Tetanus-Pertussis Vaccine
Bordetella pertussis
Diphtheria
Tetanus
Diphtheria Toxin
Diphtheria Toxoid
Immunization Schedule
Tetanus Toxoid
Poliovirus Vaccine, Inactivated
Immunization, Secondary
Diphtheria-Tetanus Vaccine
Vaccination
Pertussis Toxin
Toxoids
Virulence Factors, Bordetella
Haemophilus Vaccines
Tetanus Toxin
Vaccines, Conjugate
Diphtheria Antitoxin
Vaccines
Hemagglutinins
Drug Approval
Immunization
Vaccines, Inactivated
United States Food and Drug Administration
Corynebacterium diphtheriae
Immunoglobulin G
United States
Bacterial Vaccines
Hepatitis B Vaccines
Vaccines, Synthetic
Viral Vaccines
Meningococcal Vaccines
Immunization Programs
Haemophilus influenzae type b
Vaccines, DNA
Clostridium tetani
Enzyme-Linked Immunosorbent Assay
Mice, Inbred BALB C
Incidence
Bordetella parapertussis
AIDS Vaccines
Poliovirus Vaccines
Vaccines, Subunit
Bordetella
Product Surveillance, Postmarketing
Immunity, Cellular
Malaria Vaccines
Adjuvants, Immunologic
Bordetella bronchiseptica
Papillomavirus Vaccines
Adhesins, Bacterial
Antibody Formation
Double-Blind Method
Measles Vaccine
Recall of Tripedia vaccine. (1/163)
On January 27, 1999, the Food and Drug Administration initiated a voluntary recall of Tripedia diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), lot number 0916490, manufactured by Pasteur Merieux Connaught USA. Routine post-release stability testing completed in January 1999 indicated that the potency of the diphtheria toxoid component of this lot was below specification. The potency of the tetanus and pertussis components of this lot was acceptable. (+info)Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. (2/163)
A subanalysis of a recent cohort efficacy trial of a pertussis vaccine was performed to determine its efficacy against cough illnesses due to Bordetella parapertussis infections. Infants received four doses of either the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine or the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine at 3, 4.5, 6, and 15-18 months of age; controls received three doses of diphtheria and tetanus toxoids (DT) vaccine only. All subjects were prospectively followed for cough illnesses of > or = 7 days' duration; cases of B. parapertussis infection were confirmed by positive culture, household contact, or serology. Seventy-six cough illnesses due to B. parapertussis were identified; 24 occurred in 929 DTaP recipients, 37 in 937 DTP recipients, and 15 in 321 DT recipients, resulting in an efficacy of 50% for DTaP vaccine (95% CI [confidence interval], 5% to 74%) and 21% for DTP vaccine (95% CI, -45% to 56%). The data in the present analysis suggest that the Lederle/Takeda DTaP vaccine but not the Lederle whole-cell component DTP vaccine has efficacy against B. parapertussis infection. (+info)The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. (3/163)
The significance of reduced antibody responses to the Haemophilus influenzae type b (Hib) component of acellular pertussis-containing combination vaccines (DTaP-Hib) is unclear. A DTaP-Hib vaccine evaluated in infants vaccinated at ages 2, 3, and 4 months showed reduced anti-Hib polysaccharide IgG (geometric mean concentration [GMC], 1.23 microgram/mL; 57%, >1.0 microgram/mL). Polyribitolribosyl phosphate (PRP) and Hib conjugate (PRP-T) vaccine given as a booster during the second year of life was evaluated for the presence of immunological memory. After boosting, most children achieved anti-PRP IgG >1.0 microgram/mL, although the GMC was higher with PRP-T (88.5 microgram/mL) than with PRP vaccine (7.86 microgram/mL, P<.001). The GMC of the PRP group was higher than anticipated for naive PRP recipients of the same age. PRP-specific IgG avidity was significantly higher after boosting than after priming, providing further evidence for the generation of memory. Despite reduced immunogenicity, DTaP-Hib combination vaccines appear to prime for immunologic memory. (+info)Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. (4/163)
Mucosal delivery of vaccines is dependent on the identification of safe and effective adjuvants that can enhance the immunogenicity of protein antigens administered by nasal or oral routes. In this study we demonstrate that two mutants of Escherichia coli heat-labile toxin (LT), LTK63, which lacks ADP-ribosylating activity, and LTR72, which has partial enzyme activity, act as potent mucosal adjuvants for the nasal delivery of an acellular pertussis (Pa) vaccine. Both LTK63 and LTR72 enhanced antigen-specific serum immunoglobulin G (IgG), secretory IgA, and local and systemic T-cell responses. Furthermore, using the murine respiratory challenge model for infection with Bordetella pertussis, we demonstrated that a nasally delivered diphtheria, tetanus, and acellular pertussis (DTPa) combination vaccine formulated with LTK63 as an adjuvant conferred a high level of protection, equivalent to that generated with a parenterally delivered DTPa vaccine formulated with alum. This study also provides significant new information on the roles of the binding and enzyme components of LT in the modulation of Th1 and Th2 responses. LTK63, which lacks enzyme activity, promoted T-cell responses with a mixed Th1-Th2 profile, but LTR72, which retains partial enzyme activity, and the wild-type toxin, especially at low dose, induced a more polarized Th2-type response and very high IgA and IgG antibody titers. Our findings suggest that the nontoxic AB complex has broad adjuvant activity for T-cell responses and that the ADP-ribosyltransferase activity of the A subunit also appears to modulate cytokine production, but its effect on T-cell subtypes, as well as enhancing, may be selectively suppressive. (+info)Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. (5/163)
Immune responses to exogenous antigens in infant experimental animals display various degrees of Th2 polarization. Preliminary evidence from small human studies suggest a similar age-dependent response pattern to vaccines, but detailed investigations on vaccine immunity during infancy have not yet been undertaken. We report below the results of a comprehensive prospective study on responses to the tetanus component of the diphtheria, tetanus, acellular pertussis (DTaP) vaccine in a cohort of 55 healthy children, employing peripheral blood mononuclear cells (PBMC) collected at the 2-, 4-, and 6-month vaccinations and at 12 months. Antigen-specific production of interleukin-4 (IL-4), IL-5, IL-6, IL-9, IL-10, IL-13, and gamma interferon (IFN-gamma) was determined at each sample point, in parallel with polyclonal (phytohemagglutinin PHA-induced) cytokine responses. Our results indicate early and persistent Th2 responses to the vaccine, in contrast to a more delayed and transient pattern of IFN-gamma production. This initial disparity between the Th1 and Th2 components of the vaccine response was mirrored by patterns of polyclonally induced cytokine production, suggesting that the delayed maturation of the Th1 component of the vaccine response during infancy is secondary to developmental processes occurring within the overall Th cell system. (+info)Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. (6/163)
OBJECTIVE: To compare rates of local reactions associated with two needle sizes used to administer routine immunisations to infants. DESIGN: Randomised controlled trial. SETTING: Routine immunisation clinics in eight general practices in Buckinghamshire. PARTICIPANTS: Healthy infants attending for third primary immunisation due at 16 weeks of age: 119 infants were recruited, and 110 diary cards were analysed. INTERVENTIONS: Immunisation with 25 gauge, 16 mm, orange hub needle or 23 gauge, 25 mm, blue hub needle. MAIN OUTCOME MEASURES: Parental recordings of redness, swelling, and tenderness for three days after immunisation. RESULTS: Rate of redness with the longer needle was initially two thirds the rate with the smaller needle (relative risk 0.66 (95% confidence interval 0.45 to 0.99), P=0.04), and by the third day this had decreased to a seventh (relative risk 0.13 (0.03 to 0.56), P=0.0006). Rate of swelling with the longer needle was initially about a third that with the smaller needle (relative risk 0.39 (0.23 to 0.67), P=0.0002), and this difference remained for all three days. Rates of tenderness were also lower with the longer needle throughout follow up, but not significantly (relative risk 0.60 (0.29 to 1.25), P=0.17). CONCLUSIONS: Use of 25 mm needles significantly reduced rates of local reaction to routine infant immunisation. On average, for every five infants vaccinated, use of the longer needle instead of the shorter needle would prevent one infant from experiencing any local reaction. Vaccine manufacturers should review their policy of supplying the shorter needle in vaccine packs. (+info)Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). (7/163)
Four vaccines containing diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) are currently licensed in the United States for use among infants and young children. As of October 2000, two products, ACEL-IMUNE (a product of Lederle Laboratories) and Tripedia (Aventis Pasteur, Inc.) were licensed for the five-dose DTaP vaccination series. Two other vaccines, Infanrix (SmithKline Beecham Biologicals) and Certiva (North American Vaccine, Inc.) are licensed for the first four doses of the vaccination series, beginning with the primary series at ages 2, 4, and 6 months, and for completing the DTaP series among children who began the series with diphtheria and tetanus toxoids and whole-cell pertussis vaccine. This report supplements the statement from CDC's Advisory Committee on Immunization Practices regarding use of acellular pertussis vaccines and summarizes data regarding reactogenicity of acellular pertussis vaccines when administered as the fourth and fifth consecutive doses. Increases in the frequency and magnitude of local reactions at the injection site with increasing dose number have occurred for all currently licensed DTaP vaccines. Extensive swelling of the injected limb, sometimes involving the entire thigh or upper arm, after receipt of the fourth and fifth doses of DTaP vaccines has been demonstrated for multiple products from different manufacturers. Because data are insufficient regarding the safety, immunogenicity, and efficacy of using DTaP vaccines from different manufacturers in a mixed sequence, ACIP continues to recommend that, whenever feasible, the same brand of DTaP vaccine be used for all doses in the vaccination series. When the vaccine provider does not know or does not have available the type of DTaP vaccine previously administered, any of the licensed DTaP vaccines can be used to complete the vaccine series. (+info)Update on the supply of tetanus and diphtheria toxoids and of diphtheria and tetanus toxoids and acellular pertussis vaccine. (8/163)
During the last quarter of 2000, the U.S. Public Health Service learned of a shortage of tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) resulting from decreased production of these vaccines by the two U.S. manufacturers. Previously published recommendations outlined priorities for use of the limited supply of Td and TT. The shortage was expected to be resolved by early 2001; however, on January 10, 2001, Wyeth Lederle (Pearl River, New York) announced it had stopped production of tetanus toxoid-containing products. Although a small amount of Td is produced by the University of Massachusetts for local distribution, Aventis Pasteur (Swiftwater, Pennsylvania) is now the sole nationwide distributor of Td and TT. Aventis Pasteur is shipping limited quantities of vaccine to assure a wide distribution of available doses. (+info)A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.
Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines are a type of combination vaccine that protect against three serious diseases caused by bacteria: diphtheria, tetanus, and pertussis (also known as whooping cough).
Diphtheria is a highly contagious respiratory infection that can cause breathing difficulties, heart failure, paralysis, and even death. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, which can be severe enough to cause broken bones or suffocation. Pertussis is a highly contagious respiratory infection that causes severe coughing fits, making it difficult to breathe, eat, or drink.
The "a" in DTaP stands for "acellular," which means that the pertussis component of the vaccine contains only parts of the bacteria, rather than the whole cells used in older vaccines. This reduces the risk of side effects associated with the whole-cell pertussis vaccine while still providing effective protection against the disease.
DTaP vaccines are typically given as a series of five shots, starting at 2 months of age and ending at 4-6 years of age. Booster doses may be recommended later in life to maintain immunity. DTaP vaccines are an essential part of routine childhood immunization schedules and have significantly reduced the incidence of these diseases worldwide.
Acellular vaccines are a type of vaccine that contain one or more antigens but do not contain whole cell parts or components of the pathogen. They are designed to produce an immune response in the body that is specific to the antigen(s) contained within the vaccine, while minimizing the risk of adverse reactions associated with whole cell vaccines.
Acellular vaccines are often produced using recombinant DNA technology, where a specific gene from the pathogen is inserted into a different organism (such as yeast or bacteria) that can produce large quantities of the antigen. The antigen is then purified and used to create the vaccine.
One example of an acellular vaccine is the DTaP vaccine, which is used to protect against diphtheria, tetanus, and pertussis (whooping cough). This vaccine contains only a small portion of the pertussis bacterium, along with purified versions of the toxins produced by the bacteria. By contrast, whole cell pertussis vaccines contain entire killed bacteria, which can cause more frequent and severe side effects.
Overall, acellular vaccines offer a safer and more targeted approach to immunization than whole cell vaccines, while still providing effective protection against infectious diseases.
Whoopering Cough, also known as Pertussis, is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. It is characterized by severe coughing fits followed by a high-pitched "whoop" sound during inspiration. The disease can affect people of all ages, but it is most dangerous for babies and young children. Symptoms typically develop within 5 to 10 days after exposure and include runny nose, low-grade fever, and a mild cough. After a week or two, the cough becomes more severe and is often followed by vomiting and exhaustion. Complications can be serious, especially in infants, and may include pneumonia, seizures, brain damage, or death. Treatment usually involves antibiotics to kill the bacteria and reduce the severity of symptoms. Vaccination is available and recommended for the prevention of whooping cough.
The Diphtheria-Tetanus-Pertussis (DTaP) vaccine is a combination immunization that protects against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough).
Diphtheria is an upper respiratory infection that can lead to breathing difficulties, heart failure, paralysis, or even death. Tetanus is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, leading to "lockjaw." Pertussis is a highly contagious respiratory infection characterized by severe coughing fits, which can make it difficult to breathe and may lead to pneumonia, seizures, or brain damage.
The DTaP vaccine contains inactivated toxins (toxoids) from the bacteria that cause these diseases. It is typically given as a series of five shots, with doses administered at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age. The vaccine helps the immune system develop protection against the diseases without causing the actual illness.
It is important to note that there are other combination vaccines available that protect against these same diseases, such as DT (diphtheria and tetanus toxoids) and Tdap (tetanus, diphtheria, and acellular pertussis), which contain higher doses of the diphtheria and pertussis components. These vaccines are recommended for different age groups and may be used as booster shots to maintain immunity throughout adulthood.
'Bordetella pertussis' is a gram-negative, coccobacillus bacterium that is the primary cause of whooping cough (pertussis) in humans. This highly infectious disease affects the respiratory system, resulting in severe coughing fits and other symptoms. The bacteria's ability to evade the immune system and attach to ciliated epithelial cells in the respiratory tract contributes to its pathogenicity.
The bacterium produces several virulence factors, including pertussis toxin, filamentous hemagglutinin, fimbriae, and tracheal cytotoxin, which contribute to the colonization and damage of respiratory tissues. The pertussis toxin, in particular, is responsible for many of the clinical manifestations of the disease, such as the characteristic whooping cough and inhibition of immune responses.
Prevention and control measures primarily rely on vaccination using acellular pertussis vaccines (aP) or whole-cell pertussis vaccines (wP), which are included in combination with other antigens in pediatric vaccines. Continuous efforts to improve vaccine efficacy, safety, and coverage are essential for controlling the global burden of whooping cough caused by Bordetella pertussis.
Diphtheria is a serious bacterial infection caused by Corynebacterium diphtheriae. It typically affects the respiratory system, including the nose, throat, and windpipe (trachea), causing a thick gray or white membrane to form over the lining of these areas. This can lead to breathing difficulties, heart complications, and neurological problems if left untreated.
The bacteria can also produce a powerful toxin that can cause damage to other organs in the body. Diphtheria is usually spread through respiratory droplets from an infected person's cough or sneeze, or by contact with contaminated objects or surfaces. The disease is preventable through vaccination.
Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:
1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.
Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.
Tetanus is a serious bacterial infection caused by the bacterium Clostridium tetani. The bacteria are found in soil, dust and manure and can enter the body through wounds, cuts or abrasions, particularly if they're not cleaned properly. The bacterium produces a toxin that affects the nervous system, causing muscle stiffness and spasms, often beginning in the jaw and face (lockjaw) and then spreading to the rest of the body.
Tetanus can be prevented through vaccination, and it's important to get vaccinated if you haven't already or if your immunization status is not up-to-date. If tetanus is suspected, medical attention should be sought immediately, as it can be a life-threatening condition if left untreated. Treatment typically involves administering tetanus immune globulin (TIG) to neutralize the toxin and antibiotics to kill the bacteria, as well as supportive care such as wound cleaning and management, and in some cases, mechanical ventilation may be necessary to assist with breathing.
Diphtheria toxin is a potent exotoxin produced by the bacterium Corynebacterium diphtheriae, which causes the disease diphtheria. This toxin is composed of two subunits: A and B. The B subunit helps the toxin bind to and enter host cells, while the A subunit inhibits protein synthesis within those cells, leading to cell damage and tissue destruction.
The toxin can cause a variety of symptoms depending on the site of infection. In respiratory diphtheria, it typically affects the nose, throat, and tonsils, causing a thick gray or white membrane to form over the affected area, making breathing and swallowing difficult. In cutaneous diphtheria, it infects the skin, leading to ulcers and necrosis.
Diphtheria toxin can also have systemic effects, such as damage to the heart, nerves, and kidneys, which can be life-threatening if left untreated. Fortunately, diphtheria is preventable through vaccination with the diphtheria, tetanus, and pertussis (DTaP or Tdap) vaccine.
Diphtheria toxoid is a modified form of the diphtheria toxin that has been made harmless but still stimulates an immune response. It is used in vaccines to provide immunity against diphtheria, a serious bacterial infection that can cause breathing difficulties, heart failure, and paralysis. The toxoid is typically combined with other components in a vaccine, such as tetanus toxoid and pertussis vaccine, to form a combination vaccine that protects against multiple diseases.
The diphtheria toxoid is made by treating the diphtheria toxin with formaldehyde, which modifies the toxin's structure and makes it nontoxic while still retaining its ability to stimulate an immune response. When the toxoid is introduced into the body through vaccination, the immune system recognizes it as a foreign substance and produces antibodies against it. These antibodies then provide protection against future infections with the diphtheria bacteria.
The diphtheria toxoid vaccine is usually given as part of a routine childhood immunization schedule, starting at 2 months of age. Booster shots are recommended throughout childhood and adolescence, and adults may also need booster shots if they have not received them previously or if their immune status has changed.
An immunization schedule is a series of planned dates when a person, usually a child, should receive specific vaccines in order to be fully protected against certain preventable diseases. The schedule is developed based on scientific research and recommendations from health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
The immunization schedule outlines which vaccines are recommended, the number of doses required, the age at which each dose should be given, and the minimum amount of time that must pass between doses. The schedule may vary depending on factors such as the individual's age, health status, and travel plans.
Immunization schedules are important for ensuring that individuals receive timely protection against vaccine-preventable diseases, and for maintaining high levels of immunity in populations, which helps to prevent the spread of disease. It is important to follow the recommended immunization schedule as closely as possible to ensure optimal protection.
Tetanus toxoid is a purified and inactivated form of the tetanus toxin, which is derived from the bacterium Clostridium tetani. It is used as a vaccine to induce active immunity against tetanus, a potentially fatal disease caused by this toxin. The toxoid is produced through a series of chemical treatments that modify the toxic properties of the tetanus toxin while preserving its antigenic qualities. This allows the immune system to recognize and develop protective antibodies against the toxin without causing illness. Tetanus toxoid is often combined with diphtheria and/or pertussis toxoids in vaccines such as DTaP, Tdap, and Td.
Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.
Secondary immunization, also known as "anamnestic response" or "booster," refers to the enhanced immune response that occurs upon re-exposure to an antigen, having previously been immunized or infected with the same pathogen. This response is characterized by a more rapid and robust production of antibodies and memory cells compared to the primary immune response. The secondary immunization aims to maintain long-term immunity against infectious diseases and improve vaccine effectiveness. It usually involves administering additional doses of a vaccine or booster shots after the initial series of immunizations, which helps reinforce the immune system's ability to recognize and combat specific pathogens.
The Diphtheria-Tetanus vaccine, also known as the DT vaccine or Td vaccine (if diphtheria toxoid is not included), is a combination vaccine that protects against two potentially serious bacterial infections: diphtheria and tetanus.
Diphtheria is a respiratory infection that can cause breathing difficulties, heart problems, and nerve damage. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, particularly in the jaw and neck.
The vaccine contains small amounts of inactivated toxins (toxoids) from the bacteria that cause diphtheria and tetanus. When the vaccine is administered, it stimulates the immune system to produce antibodies that provide protection against these diseases.
In addition to protecting against diphtheria and tetanus, some formulations of the vaccine may also include protection against pertussis (whooping cough), polio, or hepatitis B. The DTaP vaccine is a similar combination vaccine that includes protection against diphtheria, tetanus, and pertussis, but uses acellular pertussis components instead of the whole-cell pertussis component used in the DT vaccine.
The Diphtheria-Tetanus vaccine is typically given as a series of shots in childhood, with booster shots recommended every 10 years to maintain immunity. It is an important part of routine childhood vaccination and is also recommended for adults who have not received the full series of shots or whose protection has waned over time.
Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.
A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.
If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.
Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.
Pertussis toxin is an exotoxin produced by the bacterium Bordetella pertussis, which is responsible for causing whooping cough in humans. This toxin has several effects on the host organism, including:
1. Adenylyl cyclase activation: Pertussis toxin enters the host cell and modifies a specific G protein (Gαi), leading to the continuous activation of adenylyl cyclase. This results in increased levels of intracellular cAMP, which disrupts various cellular processes.
2. Inhibition of immune response: Pertussis toxin impairs the host's immune response by inhibiting the migration and function of immune cells like neutrophils and macrophages. It also interferes with antigen presentation and T-cell activation, making it difficult for the body to clear the infection.
3. Increased inflammation: The continuous activation of adenylyl cyclase by pertussis toxin leads to increased production of proinflammatory cytokines, contributing to the severe coughing fits and other symptoms associated with whooping cough.
Pertussis toxin is an essential virulence factor for Bordetella pertussis, and its effects contribute significantly to the pathogenesis of whooping cough. Vaccination against pertussis includes inactivated or genetically detoxified forms of pertussis toxin, which provide immunity without causing disease symptoms.
Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.
Toxoids are inactivated bacterial toxins that have lost their toxicity but retain their antigenicity. They are often used in vaccines to stimulate an immune response and provide protection against certain diseases without causing the harmful effects associated with the active toxin. The process of converting a toxin into a toxoid is called detoxication, which is typically achieved through chemical or heat treatment.
One example of a toxoid-based vaccine is the diphtheria and tetanus toxoids (DT) or diphtheria, tetanus, and pertussis toxoids (DTaP or TdaP) vaccines. These vaccines contain inactivated forms of the diphtheria and tetanus toxins, as well as inactivated pertussis toxin in the case of DTaP or TdaP vaccines. By exposing the immune system to these toxoids, the body learns to recognize and mount a response against the actual toxins produced by the bacteria, thereby providing immunity and protection against the diseases they cause.
Virulence factors in Bordetella pertussis, the bacterium that causes whooping cough, refer to the characteristics or components of the organism that contribute to its ability to cause disease. These virulence factors include:
1. Pertussis Toxin (PT): A protein exotoxin that inhibits the immune response and affects the nervous system, leading to the characteristic paroxysmal cough of whooping cough.
2. Adenylate Cyclase Toxin (ACT): A toxin that increases the levels of cAMP in host cells, disrupting their function and contributing to the pathogenesis of the disease.
3. Filamentous Hemagglutinin (FHA): A surface protein that allows the bacterium to adhere to host cells and evade the immune response.
4. Fimbriae: Hair-like appendages on the surface of the bacterium that facilitate adherence to host cells.
5. Pertactin (PRN): A surface protein that also contributes to adherence and is a common component of acellular pertussis vaccines.
6. Dermonecrotic Toxin: A toxin that causes localized tissue damage and necrosis, contributing to the inflammation and symptoms of whooping cough.
7. Tracheal Cytotoxin: A toxin that damages ciliated epithelial cells in the respiratory tract, impairing mucociliary clearance and increasing susceptibility to infection.
These virulence factors work together to enable Bordetella pertussis to colonize the respiratory tract, evade the host immune response, and cause the symptoms of whooping cough.
Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:
1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.
Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.
Tetanus toxin, also known as tetanospasmin, is a potent neurotoxin produced by the bacterium Clostridium tetani. This toxin binds to nerve endings and is transported to the nervous system's inhibitory neurons, where it blocks the release of inhibitory neurotransmitters, particularly glycine and GABA (gamma-aminobutyric acid). As a result, it causes uncontrolled muscle contractions or spasms, which are the hallmark symptoms of tetanus disease.
The toxin has two main components: an N-terminal portion called the light chain, which is the enzymatically active part that inhibits neurotransmitter release, and a C-terminal portion called the heavy chain, which facilitates the toxin's entry into neurons. The heavy chain also contains a binding domain that allows the toxin to recognize specific receptors on nerve cells.
Tetanus toxin is one of the most potent toxins known, with an estimated human lethal dose of just 2.5-3 nanograms per kilogram of body weight when introduced into the bloodstream. Fortunately, tetanus can be prevented through vaccination with the tetanus toxoid, which is part of the standard diphtheria-tetanus-pertussis (DTaP or Tdap) immunization series for children and adolescents and the tetanus-diphtheria (Td) booster for adults.
Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.
By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.
Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.
Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.
Diphtheria Antitoxin is a medication used to treat diphtheria, a serious bacterial infection that can affect the nose, throat, and skin. It is made from the serum of animals (such as horses) that have been immunized against diphtheria. The antitoxin works by neutralizing the harmful effects of the diphtheria toxin produced by the bacteria, which can cause tissue damage and other complications.
Diphtheria Antitoxin is usually given as an injection into a muscle or vein, and it should be administered as soon as possible after a diagnosis of diphtheria has been made. It is important to note that while the antitoxin can help prevent further damage caused by the toxin, it does not treat the underlying infection itself, which requires antibiotics for proper treatment.
Like any medication, Diphtheria Antitoxin can have side effects, including allergic reactions, serum sickness, and anaphylaxis. It should only be administered under the supervision of a healthcare professional who is experienced in its use and can monitor the patient for any adverse reactions.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.
Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.
The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.
Bordetella infections are caused by bacteria called Bordetella pertussis or Bordetella parapertussis, which result in a highly contagious respiratory infection known as whooping cough or pertussis. These bacteria primarily infect the respiratory cilia (tiny hair-like structures lining the upper airways) and produce toxins that cause inflammation and damage to the respiratory tract.
The infection typically starts with cold-like symptoms, including a runny nose, sneezing, and a mild cough. After about one to two weeks, the cough becomes more severe, leading to episodes of intense, uncontrollable coughing fits that can last for several minutes. These fits often end with a high-pitched "whoop" sound as the person gasps for air. Vomiting may occur following the coughing spells.
Bordetella infections can be particularly severe and even life-threatening in infants, young children, and people with weakened immune systems. Complications include pneumonia, seizures, brain damage, and, in rare cases, death.
Prevention is primarily through vaccination, which is part of the recommended immunization schedule for children. A booster dose is also recommended for adolescents and adults to maintain immunity. Antibiotics can be used to treat Bordetella infections and help prevent the spread of the bacteria to others. However, antibiotics are most effective when started early in the course of the illness.
Hemagglutinins are proteins found on the surface of some viruses, including influenza viruses. They have the ability to bind to specific receptors on the surface of red blood cells, causing them to clump together (a process known as hemagglutination). This property is what allows certain viruses to infect host cells and cause disease. Hemagglutinins play a crucial role in the infection process of influenza viruses, as they facilitate the virus's entry into host cells by binding to sialic acid receptors on the surface of respiratory epithelial cells. There are 18 different subtypes of hemagglutinin (H1-H18) found in various influenza A viruses, and they are a major target of the immune response to influenza infection. Vaccines against influenza contain hemagglutinins from the specific strains of virus that are predicted to be most prevalent in a given season, and induce immunity by stimulating the production of antibodies that can neutralize the virus.
"Drug approval" is the process by which a regulatory agency, such as the US Food and Drug Administration (FDA), grants formal authorization for a pharmaceutical company to market and sell a drug for a specific medical condition. The approval process is based on rigorous evaluation of clinical trial data to ensure that the drug is safe and effective for its intended use.
The FDA's approval process typically involves several stages, including preclinical testing in the lab and animal studies, followed by three phases of clinical trials in human subjects. The first phase tests the safety of the drug in a small group of healthy volunteers, while the second and third phases test the drug's efficacy and side effects in larger groups of patients with the medical condition for which the drug is intended.
If the results of these studies demonstrate that the drug is safe and effective, the pharmaceutical company can submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The application includes data from the clinical trials, as well as information about the manufacturing process, labeling, and proposed use of the drug.
The FDA reviews the application and may seek input from independent experts before making a decision on whether to approve the drug. If approved, the drug can be marketed and sold to patients with the medical condition for which it was approved. The FDA continues to monitor the safety and efficacy of approved drugs after they reach the market to ensure that they remain safe and effective for their intended use.
Tetanus antitoxin is a medical preparation containing antibodies that neutralize tetanus toxin, a harmful substance produced by the bacterium Clostridium tetani. This antitoxin is used to provide immediate protection against tetanus infection in cases of wound management or as a post-exposure prophylaxis when tetanus vaccination history is incomplete or uncertain.
Tetanus, also known as lockjaw, is a severe and potentially fatal disease characterized by muscle stiffness and spasms, primarily affecting the jaw and neck muscles. The antitoxin works by binding to the tetanus toxin, preventing it from causing damage to the nervous system. It's important to note that tetanus antitoxin does not provide immunity against future tetanus infections; therefore, vaccination with a tetanus-containing vaccine is still necessary for long-term protection.
Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.
Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.
Bacterial antigens are substances found on the surface or produced by bacteria that can stimulate an immune response in a host organism. These antigens can be proteins, polysaccharides, teichoic acids, lipopolysaccharides, or other molecules that are recognized as foreign by the host's immune system.
When a bacterial antigen is encountered by the host's immune system, it triggers a series of responses aimed at eliminating the bacteria and preventing infection. The host's immune system recognizes the antigen as foreign through the use of specialized receptors called pattern recognition receptors (PRRs), which are found on various immune cells such as macrophages, dendritic cells, and neutrophils.
Once a bacterial antigen is recognized by the host's immune system, it can stimulate both the innate and adaptive immune responses. The innate immune response involves the activation of inflammatory pathways, the recruitment of immune cells to the site of infection, and the production of antimicrobial peptides.
The adaptive immune response, on the other hand, involves the activation of T cells and B cells, which are specific to the bacterial antigen. These cells can recognize and remember the antigen, allowing for a more rapid and effective response upon subsequent exposures.
Bacterial antigens are important in the development of vaccines, as they can be used to stimulate an immune response without causing disease. By identifying specific bacterial antigens that are associated with virulence or pathogenicity, researchers can develop vaccines that target these antigens and provide protection against infection.
Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.
Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).
The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).
'Corynebacterium diphtheriae' is a gram-positive, rod-shaped, aerobic bacteria that can cause the disease diphtheria. It is commonly found in the upper respiratory tract and skin of humans and can be transmitted through respiratory droplets or direct contact with contaminated objects. The bacterium produces a potent exotoxin that can cause severe inflammation and formation of a pseudomembrane in the throat, leading to difficulty breathing and swallowing. In severe cases, the toxin can spread to other organs, causing serious complications such as myocarditis (inflammation of the heart muscle) and peripheral neuropathy (damage to nerves outside the brain and spinal cord). The disease is preventable through vaccination with the diphtheria toxoid-containing vaccine.
Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.
IgG has several important functions:
1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.
IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.
I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!
Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.
There are several types of bacterial vaccines, including:
1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.
Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.
It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.
"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.
The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.
It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."
Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.
A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.
Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.
It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.
Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.
Immunization programs, also known as vaccination programs, are organized efforts to administer vaccines to populations or communities in order to protect individuals from vaccine-preventable diseases. These programs are typically implemented by public health agencies and involve the planning, coordination, and delivery of immunizations to ensure that a high percentage of people are protected against specific infectious diseases.
Immunization programs may target specific age groups, such as infants and young children, or populations at higher risk of certain diseases, such as travelers, healthcare workers, or individuals with weakened immune systems. The goals of immunization programs include controlling and eliminating vaccine-preventable diseases, reducing the morbidity and mortality associated with these diseases, and protecting vulnerable populations from outbreaks and epidemics.
Immunization programs may be delivered through a variety of settings, including healthcare facilities, schools, community centers, and mobile clinics. They often involve partnerships between government agencies, healthcare providers, non-governmental organizations, and communities to ensure that vaccines are accessible, affordable, and acceptable to the populations they serve. Effective immunization programs require strong leadership, adequate funding, robust data systems, and ongoing monitoring and evaluation to assess their impact and identify areas for improvement.
Haemophilus influenzae type b (Hib) is a bacterial subtype that can cause serious infections, particularly in children under 5 years of age. Although its name may be confusing, Hib is not the cause of influenza (the flu). It is defined medically as a gram-negative, coccobacillary bacterium that is a member of the family Pasteurellaceae.
Hib is responsible for several severe and potentially life-threatening infections such as meningitis (inflammation of the membranes surrounding the brain and spinal cord), epiglottitis (swelling of the tissue located at the base of the tongue that can block the windpipe), pneumonia, and bacteremia (bloodstream infection).
Before the introduction of the Hib vaccine in the 1980s and 1990s, Haemophilus influenzae type b was a leading cause of bacterial meningitis in children under 5 years old. Since then, the incidence of invasive Hib disease has decreased dramatically in vaccinated populations.
I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.
DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.
DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.
DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.
'Clostridium tetani' is a gram-positive, spore-forming, anaerobic bacterium that is the causative agent of tetanus. The bacteria are commonly found in soil, dust, and manure, and can contaminate wounds, leading to the production of a potent neurotoxin called tetanospasmin. This toxin causes muscle spasms and stiffness, particularly in the jaw and neck muscles, as well as autonomic nervous system dysfunction, which can be life-threatening. Tetanus is preventable through vaccination with the tetanus toxoid vaccine.
An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.
In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.
ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.
BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.
BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.
One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.
BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.
In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.
'Bordetella parapertussis' is a gram-negative, coccobacillus bacterium that can cause a respiratory infection in humans. It is one of the several species in the genus Bordetella and is closely related to Bordetella pertussis, which causes whooping cough (pertussis).
Bordetella parapertussis infection often results in symptoms similar to those of pertussis but are usually less severe. The illness is sometimes referred to as "mild whooping cough" or "whooping cough-like illness."
The bacterium primarily infects the respiratory tract, attaching to the ciliated epithelial cells lining the airways. This leads to inflammation and damage of the respiratory mucosa, causing a persistent cough, which may be accompanied by paroxysms (intense fits of coughing), inspiratory whoop, and post-tussive vomiting.
Transmission occurs through respiratory droplets when an infected person sneezes or coughs near someone else. The incubation period for Bordetella parapertussis infection is typically 7 to 10 days but can range from 5 to 21 days.
Prevention and control measures include vaccination, good hygiene practices (such as covering the mouth and nose when coughing or sneezing), and early detection and treatment of infected individuals. Antibiotics such as macrolides (e.g., azithromycin, erythromycin) are often used to treat Bordetella parapertussis infections, helping to reduce the duration of symptoms and limit transmission to others.
An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.
Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.
Poliovirus vaccines are preparations used for active immunization against poliomyelitis, a highly infectious disease caused by the poliovirus. The two types of poliovirus vaccines available are:
1. Inactivated Poliovirus Vaccine (IPV): This vaccine contains inactivated (killed) poliovirus strains of all three serotypes. IPV is typically administered through an injection, usually in combination with other vaccines. It provides a strong immune response and does not carry the risk of vaccine-associated paralytic polio (VAPP), which is a rare but serious adverse event associated with the oral poliovirus vaccine (OPV).
2. Oral Poliovirus Vaccine (OPV): This vaccine contains live attenuated (weakened) poliovirus strains of all three serotypes. OPV is administered orally and induces both humoral and intestinal immunity, which helps prevent the spread of the virus in a community. However, there is a small risk of VAPP associated with this vaccine, especially after multiple doses. In rare cases, the weakened virus can revert to its virulent form and cause paralytic polio in the vaccinated individual or their close contacts.
Both IPV and OPV have been instrumental in global efforts to eradicate polio. The World Health Organization (WHO) recommends using IPV in routine immunization programs, while using OPV during supplementary immunization activities in areas with a high risk of poliovirus transmission.
A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.
Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.
Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.
"Bordetella" is a genus of gram-negative, aerobic bacteria that are known to cause respiratory infections in humans and animals. The most well-known species within this genus is Bordetella pertussis, which is the primary causative agent of whooping cough (pertussis) in humans.
Whooping cough is a highly contagious respiratory infection that is characterized by severe coughing fits, followed by a high-pitched "whoop" sound upon inhalation. The bacteria attach to the cilia lining the respiratory tract and release toxins that damage the cilia and cause inflammation, leading to the characteristic symptoms of the disease.
Other species within the Bordetella genus include Bordetella parapertussis, which can also cause a milder form of whooping cough, and Bordetella bronchiseptica, which is associated with respiratory infections in animals but can occasionally infect humans as well.
Prevention of Bordetella infections typically involves vaccination, with vaccines available for both infants and adults to protect against B. pertussis and B. parapertussis. Good hygiene practices, such as covering the mouth and nose when coughing or sneezing, can also help prevent the spread of these bacteria.
Hexobarbital is a medication that belongs to the class of drugs called barbiturates. It is primarily used as a short-acting sedative and hypnotic agent, which means it can help induce sleep and reduce anxiety. Hexobarbital works by depressing the central nervous system, slowing down brain activity and causing relaxation and drowsiness.
It's important to note that hexobarbital is not commonly used in modern medical practice due to the availability of safer and more effective alternatives. Additionally, barbiturates like hexobarbital have a high potential for abuse and dependence, and their use is associated with several risks, including respiratory depression, overdose, and death, particularly when taken in combination with other central nervous system depressants such as alcohol or opioids.
Product surveillance, postmarketing refers to the ongoing monitoring and evaluation of a pharmaceutical or medical device product after it has been approved and released on the market. This process is used to detect any safety issues, adverse effects, or product performance concerns that may not have been identified during clinical trials. The data collected from postmarketing surveillance helps regulatory agencies, such as the U.S. Food and Drug Administration (FDA), to make informed decisions about the continued use, modification, or withdrawal of a product from the market. Postmarketing surveillance is an essential component of post-market risk management and helps ensure the safety and efficacy of medical products throughout their lifecycle.
Cellular immunity, also known as cell-mediated immunity, is a type of immune response that involves the activation of immune cells, such as T lymphocytes (T cells), to protect the body against infected or damaged cells. This form of immunity is important for fighting off infections caused by viruses and intracellular bacteria, as well as for recognizing and destroying cancer cells.
Cellular immunity involves a complex series of interactions between various immune cells and molecules. When a pathogen infects a cell, the infected cell displays pieces of the pathogen on its surface in a process called antigen presentation. This attracts T cells, which recognize the antigens and become activated. Activated T cells then release cytokines, chemicals that help coordinate the immune response, and can directly attack and kill infected cells or help activate other immune cells to do so.
Cellular immunity is an important component of the adaptive immune system, which is able to learn and remember specific pathogens in order to mount a faster and more effective response upon subsequent exposure. This form of immunity is also critical for the rejection of transplanted organs, as the immune system recognizes the transplanted tissue as foreign and attacks it.
A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.
Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.
The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.
Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.
Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).
The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.
It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.
'Bordetella bronchiseptica' is a gram-negative, aerobic bacterium that primarily colonizes the respiratory tract of animals, including dogs, cats, and rabbits. It can also cause respiratory infections in humans, particularly in individuals with compromised immune systems or underlying lung diseases.
The bacterium produces several virulence factors, such as adhesins, toxins, and proteases, which allow it to attach to and damage the ciliated epithelial cells lining the respiratory tract. This can lead to inflammation, bronchitis, pneumonia, and other respiratory complications.
'Bordetella bronchiseptica' is closely related to 'Bordetella pertussis', the bacterium that causes whooping cough in humans. However, while 'Bordetella pertussis' is highly adapted to infecting humans, 'Bordetella bronchiseptica' has a broader host range and can cause disease in a variety of animal species.
In animals, 'Bordetella bronchiseptica' is often associated with kennel cough, a highly contagious respiratory infection that spreads rapidly among dogs in close quarters, such as boarding facilities or dog parks. Vaccines are available to prevent kennel cough caused by 'Bordetella bronchiseptica', and they are often recommended for dogs that are at high risk of exposure.
Intranasal administration refers to the delivery of medication or other substances through the nasal passages and into the nasal cavity. This route of administration can be used for systemic absorption of drugs or for localized effects in the nasal area.
When a medication is administered intranasally, it is typically sprayed or dropped into the nostril, where it is absorbed by the mucous membranes lining the nasal cavity. The medication can then pass into the bloodstream and be distributed throughout the body for systemic effects. Intranasal administration can also result in direct absorption of the medication into the local tissues of the nasal cavity, which can be useful for treating conditions such as allergies, migraines, or pain in the nasal area.
Intranasal administration has several advantages over other routes of administration. It is non-invasive and does not require needles or injections, making it a more comfortable option for many people. Additionally, intranasal administration can result in faster onset of action than oral administration, as the medication bypasses the digestive system and is absorbed directly into the bloodstream. However, there are also some limitations to this route of administration, including potential issues with dosing accuracy and patient tolerance.
Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.
There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).
Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.
It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.
Bacterial adhesins are proteins or structures on the surface of bacterial cells that allow them to attach to other cells or surfaces. This ability to adhere to host tissues is an important first step in the process of bacterial infection and colonization. Adhesins can recognize and bind to specific receptors on host cells, such as proteins or sugars, enabling the bacteria to establish a close relationship with the host and evade immune responses.
There are several types of bacterial adhesins, including fimbriae, pili, and non-fimbrial adhesins. Fimbriae and pili are thin, hair-like structures that extend from the bacterial surface and can bind to a variety of host cell receptors. Non-fimbrial adhesins are proteins that are directly embedded in the bacterial cell wall and can also mediate attachment to host cells.
Bacterial adhesins play a crucial role in the pathogenesis of many bacterial infections, including urinary tract infections, respiratory tract infections, and gastrointestinal infections. Understanding the mechanisms of bacterial adhesion is important for developing new strategies to prevent and treat bacterial infections.
Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:
1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.
Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.
The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.
A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.
The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.
Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.
Cross-protection is a term used in immunology and vaccinology that refers to the ability of a vaccine or natural infection with one strain of a microorganism (such as a virus or bacteria) to provide protection against other, related strains. This occurs because the immune response elicited by the initial exposure also recognizes and targets certain common features present in the related strains.
In the context of vaccines, cross-protection can be an important factor in designing broadly protective vaccines that can cover multiple strains or serotypes of a pathogen, thus reducing the need for individual vaccines against each strain. However, the degree of cross-protection can vary depending on the specific microorganisms and antigens involved.
It's important to note that cross-protection is not always complete or long-lasting, and additional research may be needed to fully understand its mechanisms and limitations.